Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01940471 · ClinicalTrials.gov registry record · Phase 3
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 875
- Enrollment target
NCT01940471 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 875 participants.
The verdict
NCT01940471, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 875 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection.
Interventions
- DRUG TAF
- DRUG TDF
- DRUG TDF Placebo
- DRUG TAF Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 875 participants |
| Start Date | 2013-09-11 |
| Est. Completion | 2022-10-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01940471
The ClinicalTrials.gov registry entry for NCT01940471 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 875 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which TAF is the first listed.
NCT01940471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01940471 about?
NCT01940471 is a clinical study titled "Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen". The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection...
What is the current status of trial NCT01940471?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 875 participants. The study started on 2013-09-11. Estimated completion is 2022-10-13.
What interventions are being tested in trial NCT01940471?
The interventions under investigation include: TAF (DRUG), TDF (DRUG), TDF Placebo (DRUG), TAF Placebo (DRUG).
Who is sponsoring clinical trial NCT01940471?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.